SM
ODT

Sabby Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Sabby Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-354
Closed -$475K – 165
2020
Q3 		$475K Sell
354
-121
-25% -$3.43K 0.07% 84
2020
Q2 		$2.01M Buy
475
+30
+7% +$971 0.4% 34
2020
Q1 		$1.23M Buy
+445
New +$13K 0.51% 22

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sabby Management's ODT Position: Q3 2021 in Review

Sabby Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2021, closing a stake of 14,979 shares — an estimated $52K sold.

Sabby Management first reported a position in ODT in Q4 2017 and held it in 15 quarters. The position peaked at $20.6M in Q4 2017. 58 funds tracked by Wall St. Rank hold ODT as of Q3 2021.

  • Sabby Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Sabby Management sold 14,979 Odonate Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $52K.
  • Sabby Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 15 quarters.
  • Sabby Management's Odonate Therapeutics, Inc. Common Stock position peaked at $20.6M in Q4 2017.
  • 58 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.